Clinical trials: Pulmonary Embolism
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Venous Thrombosis and Pulmonary Embolism
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
- Trial name
- COSIMO (NCT02742623)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- 10 sites in Australia, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Bayer
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thrombosis
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous…
- Trial name
- SATORI (NCT01805544)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- Bayer
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 3 (NCT00361894)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 143 sites in Austria, Belgium and 17 more
- Volunteers
- 2,531 people
- Sponsor
- Bayer
Deep Vein Thrombosis, Pulmonary Embolism
A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay
In patients with symptoms of Venous Thromboembolism (VTE) (mainly deep vein thrombosis (DVT) or pulmonary embolism (PE)), the study will evaluate the agreement between the D-Dimer measurements from the LumiraDx POC D-Dimer assay…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- EMBOL1 (NCT04737954)
- Testing
- Venepuncture, Fingerstick
- Where
- 13 sites in Germany, United Kingdom
- Volunteers
- 679 people
- Sponsor
- LumiraDx UK Limited
Pulmonary Embolism
Catheter Thrombectomy in Patients With Massive Pulmonary Embolism
Official Title: Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism Study Population: Patients >/= 18 years of age with massive pulmonary embolism suitable for mechanical…
- Trial name
- NCT00314002
- Testing
- Mechanical Thrombectomy
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 50 people
- Sponsor
- Straub Medical AG
Thrombosis, Venous
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of…
- Trial name
- NCT00911157
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 24 sites in Japan
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Pulmonary Embolism
Evaluation of the Magneto eTrieve™ PE Kit for Endovascular Thrombectomy in Subjects With Acute Pulmonary Embolism
Prospective, multi-center, open-label, single-arm clinical study of the safety and effectiveness of the eTrieve™ in subjects presenting with signs and symptoms of acute intermediate-risk pulmonary embolism
- Trial name
- eTrieve II (NCT05821426)
- Testing
- eTrieve PE Kit
- Volunteers
- 130 people
- Sponsor
- Magneto Thrombectomy Solutions
Deep Venous Thrombosis, Pulmonary Embolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
The purpose of this study is to demonstrate the ability of STA® Liatest® D-Di combined with a clinical pretest probability (PTP) to safely exclude pulmonary embolism (PE) or Deep Venous Thrombosis (DVT) in a 3 month follow-up.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, D-dimer
- Trial name
- DiET (NCT01221805)
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 2,040 people
- Sponsor
- Diagnostica Stago
Venous Thromboembolism
Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty
Venous thromboembolic events (VTE), either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty.
- Trial name
- ACOR (NCT01984190)
- Where
- 10 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 13 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thrombosis
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
To study the safety and effectiveness of several doses of PD 0348292 compared to enoxaparin in preventing blood clots in the lungs or deep leg veins of patients after knee surgery
- Trial name
- NCT00306254
- Testing
- PD 0348292, Enoxaparin
- Where
- 134 sites in United States, Australia and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Pfizer
Stroke, Acute, Venous Thromboembolism
GEKO Venous Thromboembolism Prevention Study
This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to…
- Conditions
- Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT05476913
- Testing
- geko™ device
- Where
- 18 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- Firstkind Ltd
Thrombosis, Cerebral Ischemia
Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer
This study is designed to determine the safety, pharmacokinetics and pharmacodynamics of a single intravenous dose of TS23 in healthy adults.
- Conditions
- Thrombosis, Cerebral Ischemia, Venous Thrombosis, Pulmonary Embolism
- Trial name
- TS23Phase1a (NCT03001544)
- Testing
- TS23
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Translational Sciences, Inc.
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Submassive Pulmonary Embolism
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
An exploratory, multicenter, randomized, placebo-controlled, double blind, dose escalation study comparing a standard therapy for submassive pulmonary embolism (Enoxaparin sodium) to a combined therapy of Drotrecogin alfa…
- Trial name
- NCT00191724
- Testing
- Drotrecogin Alfa (Activated), Enoxaparin
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Pulmonary Embolism
Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System
The purpose of this European Post Market Follow-up Plan is designed to evaluate the safety, efficacy, adverse events and any new information that may surface regarding the use of the AngioJet Ultra PE Thrombectomy Catheter System…
- Trial name
- PERFUSE (NCT01638468)
- Testing
- AngioJet Ultra PE Thrombectomy System
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 7 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02923115
- Testing
- DS-1040b, Enoxaparin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 134 people
- Sponsor
- Daiichi Sankyo
Deep Venous Thromboses, Pulmonary Embolism
ThRombosis ExclUsion STudy
Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative…
- Conditions
- Deep Venous Thromboses, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- TRUST (NCT03477968)
- Testing
- DDimer test
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 5,935 people
- Sponsor
- Diagnostica Stago